PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)

• A. R. Mato,
• W. G. Wierda,
• J. M. Pagel,
• M. S. Davids,
• P. L. Zinzani,
• Y. Lu,
• H. Liu,
• S. Shahda,
• C. C. Leow,
• C. S. Tam,
• J. A. Woyach,
• T. A. Eyre

Affiliations

A. R. Mato

1 Memorial Sloan Kettering Cancer Center, New York

W. G. Wierda

2 University of Texas MD Anderson Cancer Center, Houston

J. M. Pagel

3 Loxo Oncology at Lilly, Stamford

M. S. Davids

4 Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America

P. L. Zinzani

5 Institute of Hematology “Seràgnoli”, University of Bologna, Bologna, Italy

Y. Lu

6 Elli Lily and Company, Indianapolis, United States of America

H. Liu

3 Loxo Oncology at Lilly, Stamford

S. Shahda

3 Loxo Oncology at Lilly, Stamford

C. C. Leow

3 Loxo Oncology at Lilly, Stamford

C. S. Tam

7 Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Australia

J. A. Woyach

8 The Ohio State University Comprehensive Cancer Center, Columbus, United States of America

T. A. Eyre

9 Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom